IP Library Assignment 054102/0821
Patent Assignment
Reel/Frame 054102/0821

Change of Name

Recorded: 2020-10-16 Pages: 4
Assignor
SEATTLE GENETICS, INC.
Executed: 2020-10-06
Assignee
SEAGEN INC.
21823 30TH DRIVE SE, BOTHELL, WASHINGTON, 98021
Covered Properties (39)
Methods of Treating HER2 Positive Breast Cancer with Tucatinib in Combination with Ado-Trastuzumab Emtansine
Application: 62/935,989 →
Methods of Treating HER2 Positive Breast Cancer with Tucatinib in Combination with an Anti-HER2 Antibody-Drug Conjugate
Application: 62/945,321 →
Treatment of HER2 Positive Cancers
Application: 16/607,850 →
Publication: US 2020/0188401
Weekly Dosing Regimens for Anti-CD30 Vc-Pab-Mmae Antibody Drug-Conjugates
Application: 16/128,363 →
Publication: US 2018/0369317
Weekly Dosing Regimens for Anti-CD30 Vc-Pab-Mmae Antibody Drug-Conjugates
Application: 16/904,261 →
Publication: US 2020/0306336
Anti-Ntb-A Antibodies and Related Compositions and Methods
Application: 15/739,363 →
Publication: US 2018/0169257
Anti-AVB6 Antibodies and Antibody-Drug Conjugates
Application: 62/943,959 →
CD19 Binding Agents and Uses Thereof
Application: 15/897,063 →
Publication: US 2018/0326087
Detection and Treatment of CD30+ Cancers
Application: 16/571,035 →
Publication: US 2020/0110091
Methods of Reducing Side Effects of Anti-CD30 Antibody Drug Conjugate Therapy
Application: 16/755,403 →
Publication: US 2021/0221901
Modulating the Immune Response Using Antibody-Drug Conjugates
Application: 16/755,091 →
Publication: US 2020/0239585
Methods of Reducing Side Effects of Anti-CD30 Antibody Drug Conjugate Therapy
Application: 16/760,916 →
Publication: US 2022/0226439
Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
Application: 16/362,125 →
Publication: US 2019/0290775
Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
Application: 16/589,914 →
Publication: US 2020/0102399
CD33 Antibodies and Use of Same to Treat Cancer
Application: 16/942,647 →
Publication: US 2021/0047404
Dosage and Administration of Non-Fucosylated Anti-CD40 Antibodies
Application: 15/522,614 →
Publication: US 2017/0333556
Dosage and Administration of Non-Fucosylated Anti-CD40 Antibodies
Application: 15/411,741 →
Publication: US 2017/0137528
Anti-TIGIT Antibodies
Application: 16/541,575 →
Publication: US 2020/0040082
Anti-TIGIT Antibodies
Application: 16/547,824 →
Publication: US 2020/0062859
Bcma Antibodies and Use of Same to Treat Cancer and Immunological Disorders
Application: 15/999,346 →
Publication: US 2019/0194338
Bcma Antibodies and Use of Same to Treat Cancer and Immunological Disorders
Application: 16/411,867 →
Publication: US 2020/0002431
Humanized Antibodies to Liv-1 and Use of Same to Treat Cancer
Patent: 48,959 →
Application: 15/862,389 →
Humanized Antibodies to Liv-1 and Use of Same to Treat Cancer
Application: 16/784,069 →
Publication: US 2020/0165335
Combination Therapy Using a LIV1-Adc and a Chemotherapeutic
Application: 16/085,511 →
Publication: US 2019/0085091
Humanized Anti-LIV1 Antibodies for the Treatment of Breast Cancer
Application: 16/768,020 →
Publication: US 2020/0283540
Acid-Mediated Assay for Analyzing Ligand-Drug Conjugates
Application: 16/765,059 →
Publication: US 2020/0363425
High Performance Liquid Chromatography Quantification of Excipients
Application: 62/948,357 →
Anti-Ntb-A Antibodies and Related Compositions and Methods
Application: 16/553,525 →
Publication: US 2019/0375841
Hydrophilic Antibody-Drug Conjugates
Application: 15/118,031 →
Publication: US 2017/0216391
Intact Mass Determination of Protein Conjugated Agent Compounds
Application: 15/925,639 →
Publication: US 2018/0275137
Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates and Inhibitors of the PI3K-Akt Mtor Pathway
Application: 16/226,509 →
Publication: US 2019/0184029
Process for the Preparation of Drug Linker Compounds
Application: 16/768,027 →
Publication: US 2020/0360532
Uveal Melanoma Treatment
Application: 63/085,765 →
Treatment for Cancer
Application: 63/016,247 →
Humanized Anti-CD70 Binding Agents and Uses Thereof
Application: 16/869,322 →
Publication: US 2021/0002380
CD47 Antibodies and Uses Thereof for Treating Cancer
Application: 16/203,809 →
Publication: US 2019/0185561
Camptothecin Conjugates
Alternative Processes for the Preparation of Tubulysins and Intermediates Thereof
Anti-Tigit Antibodies
Related Assignments (24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 14, 2017
From: GARDAI, SHYRA; LAW, CHE-LEUNG; YANG, JING; NEFF-LAFORD, HALEY
To: SEATTLE GENETICS, INC.
Reel/Frame 041252/0768 →
Assignment of Assignor's Interest Mar 25, 2019
From: CAO, ANTHONY TOA; GARDAI, SHYRA JANE
To: SEATTLE GENETICS, INC.
Reel/Frame 048690/0360 →
Assignment of Assignor's Interest Aug 23, 2019
From: PRINZ, BIANKA
To: ADIMAB LLC
Reel/Frame 050153/0980 →
Assignment of Assignor's Interest Aug 23, 2019
From: PRINZ, BIANKA
To: ADIMAB LLC
Reel/Frame 050153/0866 →
Assignment of Assignor's Interest Aug 23, 2019
From: PIASECKI, JULIA C.; BEERS, COURTNEY; PETERSON, SCOTT
To: CASCADIAN THERAPEUTICS, INC.
Reel/Frame 050153/0962 →
Assignment of Assignor's Interest Aug 23, 2019
From: PIASECKI, JULIA C.; BEERS, COURTNEY; PETERSON, SCOTT
To: CASCADIAN THERAPEUTICS, INC.
Reel/Frame 050153/0856 →
Assignment of Assignor's Interest Sep 3, 2019
From: CASCADIAN THERAPEUTICS, INC.
To: ADIMAB LLC
Reel/Frame 050245/0770 →
Assignment of Assignor's Interest Sep 3, 2019
From: CASCADIAN THERAPEUTICS, INC.
To: ADIMAB LLC
Reel/Frame 050245/0730 →
Assignment of Assignor's Interest Sep 6, 2019
From: ADIMAB LLC
To: SEATTLE GENETICS, INC.
Reel/Frame 050289/0228 →
Assignment of Assignor's Interest Oct 9, 2019
From: MANLEY, THOMAS; JOSEPHSON, NEIL
To: SEATTLE GENETICS, INC.
Reel/Frame 050670/0843 →
Assignment of Assignor's Interest Dec 6, 2019
From: WALKER, LUKE
To: SEATTLE GENETICS, INC.
Reel/Frame 051206/0113 →
Assignment of Assignor's Interest Dec 13, 2019
From: PETERSON, SCOTT; GARDAI, SHYRA
To: SEATTLE GENETICS, INC.
Reel/Frame 051276/0178 →
Assignment of Assignor's Interest Dec 13, 2019
From: PIASECKI, JULIA C.; BEERS, COURTNEY
To: CASCADIAN THERAPEUTICS, INC.
Reel/Frame 051276/0079 →
Assignment of Assignor's Interest Dec 13, 2019
From: PRINZ, BIANKA
To: ADIMAB LLC
Reel/Frame 051276/0106 →
Assignment of Assignor's Interest Dec 13, 2019
From: PETERSON, SCOTT; GARDAI, SHYRA
To: SEATTLE GENETICS, INC.
Reel/Frame 051276/0119 →
Assignment of Assignor's Interest Dec 13, 2019
From: ADIMAB LLC
To: SEATTLE GENETICS, INC.
Reel/Frame 051276/0132 →
Assignment of Assignor's Interest Dec 13, 2019
From: CASCADIAN THERAPEUTICS, INC.
To: SEATTLE GENETICS, INC.
Reel/Frame 051276/0158 →
Assignment of Assignor's Interest Dec 13, 2019
From: PETERSON, SCOTT; GARDAI, SHYRA
To: SEATTLE GENETICS, INC.
Reel/Frame 051276/0189 →
Assignment of Assignor's Interest Feb 6, 2020
From: WALKER, LUKE
To: SEATTLE GENETICS, INC.
Reel/Frame 051739/0919 →
Assignment of Assignor's Interest Feb 28, 2020
From: RYAN, MAUREEN; WESTENDORF, LORI; MEYER, ERIC BRADLEY; KOSTNER, HEATHER JEAN
To: SEATTLE GENETICS, INC.
Reel/Frame 051962/0053 →
Assignment of Assignor's Interest Sep 3, 2020
From: GARDAI, SHYRA; LAW, CHE-LEUNG; PENG, STANFORD; YANG, JING
To: SEATTLE GENETICS, INC.
Reel/Frame 053688/0722 →
Assignment of Assignor's Interest Oct 28, 2020
From: MANLEY, THOMAS; JOSEPHSON, NEIL
To: SEATTLE GENETICS, INC.
Reel/Frame 054199/0613 →
Assignment of Assignor's Interest Nov 13, 2020
From: CASCADIAN THERAPEUTICS, INC.
To: SEATTLE GENETICS, INC.
Reel/Frame 054365/0943 →
Assignment of Assignor's Interest Nov 13, 2020
From: PETERSON, SCOTT; WALKER, LUKE
To: CASCADIAN THERAPEUTICS, INC.
Reel/Frame 054365/0912 →